1887
Volume 2013, Issue 4
  • ISSN: 2305-7823
  • E-ISSN:

There is no abstract available for this article.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2013.39
2014-02-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2013/4/gcsp.2013.39.html?itemId=/content/journals/10.5339/gcsp.2013.39&mimeType=html&fmt=ahah

References

  1. [1]. Hall   J., , Dib   N. . The path from pre-clinical research to FDA approval. . J Cardiovasc Transl Res . 2008; ;1: 2 : 93– 94 .
    [Google Scholar]
  2. [2]. Stamler   J. . The problem of elevated blood cholesterol. . Am J Public Health Nations Health . 1960; ;50: 3 Pt 2 : 14– 19 .
    [Google Scholar]
  3. [3]. Kannel   WB., , Dawber   TR., , Friedman   GD., , Glennon   WE., , McNamara   PM. . Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the framingham study. . Ann Intern Med . 1964; ;61: : 888– 899 .
    [Google Scholar]
  4. [4]. Kannel   WB., , Castelli   WP., , McNamara   PM. . Serum lipid fractions and risk of coronary heart disease. The Framingham study. . Minn Med . 1969; ;52: : 1225– 1230 .
    [Google Scholar]
  5. [5]. Hovingh   GK., , Davidson   MH., , Kastelein   JJP., , O'Connor   AM. . Diagnosis and treatment of familial hypercholesterolaemia. . Eur Heart J . 2013; ;34: 13 : 962– 971 .
    [Google Scholar]
  6. [6]. Ibrahim   M., , El-Hamamsy   I., , Barbir   M., , Yacoub   MH. . Translational lessons from a case of combined heart and liver transplantation for familial hypercholesterolemia 20 years post-operatively. . J Cardiovasc Transl Res . 2012; ;5: 3 : 351– 358 .
    [Google Scholar]
  7. [7]. Goldstein   JL., , Brown   MS. . Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. . Proc Natl Acad Sci U S A . 1973; ;70: : 2804– 2808 .
    [Google Scholar]
  8. [8]. Goldstein   JL., , Brown   MS. . Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. . J Biol Chem . 1974; ;249: : 5153– 5162 .
    [Google Scholar]
  9. [9]. Abifadel   M., , Varret   M., , Rabés   JP., , Allard   D., , Ouguerram   K., , Devillers   M., , Cruaud   C., , Benjannet   S., , Wickham   L., , Erlich   D., , Derré   A., , Villéger   L., , Farnier   M., , Beucler   I., , Bruckert   E., , Chambaz   J., , Chanu   B., , Lecerf   JM., , Luc   G., , Moulin   P., , Weissenbach   J., , Prat   A., , Krempf   M., , Junien   C., , Seidah   NG., , Boileau   C. . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. . Nat Genet . 2003; ;34: : 154– 156 .
    [Google Scholar]
  10. [10]. Leren   TP. . Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. . Clin Genet . 2004; ;65: : 419– 422 .
    [Google Scholar]
  11. [11]. Cohen   J., , Pertsemlidis   A., , Kotowski   IK., , Graham   R., , Garcia   CK., , Hobbs   HH. . Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. . Nat Genet . 2005; ;37: : 161– 165 .
    [Google Scholar]
  12. [12]. Chan   JC., , Piper   DE., , Cao   Q., , Liu   D., , King   C., , Wang   W., , Tang   J., , Liu   Q., , Higbee   J., , Xia   Z., , Di   Y., , Shetterly   S., , Arimura   Z., , Salomonis   H., , Romanow   WG., , Thibault   ST., , Zhang   R., , Cao   P., , Yang   XP., , Yu   T., , Lu   M., , Retter   MW., , Kwon   G., , Henne   K., , Pan   O., , Tsai   MM., , Fuchslocher   B., , Yang   E., , Zhou   L., , Lee   KJ., , Daris   M., , Sheng   J., , Wang   Y., , Shen   WD., , Yeh   WC., , Emery   M., , Walker   NP., , Shan   B., , Schwarz   M., , Jackson   SM. . A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. . Proc Natl Acad Sci U S A . 2009; ;106: : 9820– 9825 .
    [Google Scholar]
  13. [13]. Ni   YG., , Di Marco   S., , Condra   JH., , Peterson   LB., , Wang   W., , Wang   F., , Pandit   S., , Hammond   HA., , Rosa   R., , Cummings   RT., , Wood   DD., , Liu   X., , Bottomley   MJ., , Shen   X., , Cubbon   RM., , Wang   SP., , Johns   DG., , Volpari   C., , Hamuro   L., , Chin   J., , Huang   L., , Zhao   JZ., , Vitelli   S., , Haytko   P., , Wisniewski   D., , Mitnaul   LJ., , Sparrow   CP., , Hubbard   B., , Carfí   A., , Sitlani   A. . A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. . J Lipid Res . 2011; ;52: : 78– 86 .
    [Google Scholar]
  14. [14]. Liang   H., , Chaparro-Riggers   J., , Strop   P., , Geng   T., , Sutton   JE., , Tsai   D., , Bai   L., , Abdiche   Y., , Dilley   J., , Yu   J., , Wu   S., , Chin   SM., , Lee   NA., , Rossi   A., , Lin   JC., , Rajpal   A., , Pons   J., , Shelton   DL. . Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. . J Pharmacol Exp Ther . 2012; ;340: : 228– 236 .
    [Google Scholar]
  15. [15]. Frank-Kamenetsky   M., , Grefhorst   A., , Anderson   NN., , Racie   TS., , Bramlage   B., , Akinc   A., , Butler   D., , Charisse   K., , Dorkin   R., , Fan   Y., , Gamba-Vitalo   C., , Hadwiger   P., , Jayaraman   M., , John   M., , Jayaprakash   KN., , Maier   M., , Nechev   L., , Rajeev   KG., , Read   T., , Röhl   I., , Soutschek   J., , Tan   P., , Wong   J., , Wang   G., , Zimmermann   T., , de Fougerolles   A., , Vornlocher   HP., , Langer   R., , Anderson   DG., , Manoharan   M., , Koteliansky   V., , Horton   JD., , Fitzgerald   K. . Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. . Proc Natl Acad Sci U S A . 2008; ;105: : 11915– 11920 .
    [Google Scholar]
  16. [16]. Fitzgerald   K., , Frank-Kamenetsky   M., , Shulga-Morskaya   S., , Liebow   A., , Bettencourt   BR., , Sutherland   JE., , Hutabarat   RM., , Clausen   VA., , Karsten   V., , Cehelsky   J., , Nochur   SV., , Kotelianski   V., , Vaishnaw   AK., , Gollob   JA., , Simon   A. . Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. . Lancet . 2014; ;383: : 60– 68 , doi:10.1016/S0140-6736(13)61914-5. Published Online: 03 October 2013 .
    [Google Scholar]
  17. [17]. Sullivan   D., , Olsson   AG., , Scott   R., , Kim   JB., , Xue   A., , Gebski   V., , Wasserman   SM., , Stein   EA. . Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. . JAMA . 2012; ;308: : 2497– 2506 .
    [Google Scholar]
  18. [18]. Stein   EA., , Mellis   S., , Yancopoulos   GD., , Stahl   N., , Logan   D., , Smith   WB., , Lisbon   E., , Gutierrez   M., , Webb   C., , Wu   R., , Du   Y., , Kranz   T., , Gasparino   E., , Swergold   GD. . Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. . N Engl J Med . 2012; ;366: : 1108– 1118 .
    [Google Scholar]
  19. [19]. Koren   MJ., , Giugliano   RP., , Raal   FJ., , Sullivan   D., , Bolognese   M., , Langslet   G., , Civeira   F., , Somaratne   R., , Nelson   P., , Liu   T., , Scott   R., , Wasserman   SM., , Sabatine   MS., , for the OSLER Investigators. . Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-Week results from the open-label study of long-term evaluation against LDL-C (OSLER) Randomized Trial. . Circulation ., CIRCULATIONAHA.113.007012–(2013). doi:10.1161/CIRCULATIONAHA.113.007012 .
    [Google Scholar]
  20. [20]. Shan   L., , Pang   L., , Zhang   R., , Murgolo   NJ., , Lan   H., , Hedrick   JA. . PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. . Biochem Biophys Res Commun . 2008; ;375: : 69– 73 .
    [Google Scholar]
  21. [21]. Melone   M., , Wilsie   L., , Palyha   O., , Strack   A., , Rashid   S. . Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. . J Am Coll Cardiol . 2012; ;59: 19 : 1697– 1705 .
    [Google Scholar]
  22. [22]. Weikert   C., , Westphal   S., , Berger   K., , Dierkes   J., , Möhlig   M., , Spranger   J., , Rimm   EB., , Willich   SN., , Boeing   H., , Pischon   T. . Plasma resistin levels and risk of myocardial infarction and ischemic stroke. . J Clin Endocrinol Metab . 2008; ;93: 7 : 2647– 2653 .
    [Google Scholar]
  23. [23]. Hassan   M., , Latif   N., , Yacoub   M. . Adipose tissue: friend or foe?.   Nat Rev Cardiol . 2012; ;9: : 689– 702 .
    [Google Scholar]
  24. [24]. Sahebkar   A. . Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors. . Nat Rev Cardiol . 2014; ;11: 1 : 12 .
    [Google Scholar]
  25. [25]. Goldstein   JL. . Juxtapositions in trafalgar square: tip-offs to creativity in art and science. . Nat Med . 2013; ;19: : 1222– 1226 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2013.39
Loading
/content/journals/10.5339/gcsp.2013.39
Loading

Data & Media loading...

Supplements

Supplementary File 1

  • Article Type: Editorial
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error